Sep. 22, 2011 Researchers at Weill Cornell Medical College and GHESKIO (Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes) have shown that early treatment of HIV not only saves lives but is also cost-effective.
Results are published in the online journal PLoS Medicine.
Before 2009, the World Health Organization (WHO) recommended waiting to initiate antiretroviral therapy (ART) for HIV until a patient's CD4+ T cells fall below 200 cells per cubic millimeter. But in that year, a randomized clinical trial completed by Weill Cornell researchers at the GHESKIO clinic in Port-au-Prince, Haiti, demonstrated that early ART decreased mortality by 75 percent in HIV-infected adults with a CD4 cell count between 200 and 350 cells/mm3. As a result, the WHO now recommends that ART is started in HIV-infected people when their CD4 cell count falls below 350 cells/mm3.
The new study, conducted by researchers at Weill Cornell Medical College, GHESKIO, and Brigham and Women's Hospital in Boston sought to evaluate if the revised WHO recommendation is cost-effective and if its benefits outweigh its costs. A medical intervention is generally considered cost-effective if it costs less than three times a country's per capita gross domestic product (GDP) per year of life saved (YLS).
The researchers used data from the previous randomized trial to compare the cost-effectiveness of early versus standard ART. They included in their analysis the use and costs of ART, other medications, laboratory tests, outpatient visits, radiography, procedures and hospital services. Patients who received early ART had higher average costs for ART but lower costs for other aspects of their treatment than patients who received standard ART. When the costs of research-related tests were excluded, the incremental cost-effectiveness ratio after three years for early ART compared with standard ART was US $2,050/YLS.
"Because the Haitian GDP per capita is US $785, these findings suggest that, in Haiti, early ART is a cost-effective intervention over the observation period of the trial," says lead author Dr. Serena P. Koenig, assistant professor at Brigham and Women's Hospital.
"The incremental cost-effectiveness ratios calculated in our study are probably conservative because they did not consider the clinical benefits of early ART that continue beyond three years -- early ART is associated with lower longer-term mortality than standard ART -- or the benefit of early ART on disability and quality of life," says senior author Dr. Bruce R. Schackman, associate professor of public health and chief of the Division of Health Policy at Weill Cornell Medical College.
"This study suggests that the new WHO guidelines for ART initiation can be cost-effective in resource-poor settings," says Dr. Jean W. Pape, founder and director of GHESKIO and professor of medicine at Weill Cornell Medical College. "Despite substantial budget and logistical constraints to implementing earlier treatment," he continues, "policymakers should allocate resources to maximize their ability to implement the new guidelines."
The paper's other authors are, from Weill Cornell Medical College, Dr. Daniel W. Fitzgerald, Dr. Warren D. Johnson, Dr. Jean W. Pape, Dr. Heejung Bang and Ms. Alison Edwards; and from GHESKIO, Dr. Patrice Severe, Dr. Marc Antoine Jean Juste, Dr. Alex Ambroise, Dr. Cynthia Riviere, Ms. Jessica Hippolyte, Mr. Jolion McGreevy, Mr. Serge Marcelin and Dr. Rode Secours.
Funding for the study was provided by the U.S. National Institutes of Allergy and Infectious Diseases, the Fogarty International Center, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Fondation Mérieux, among others.
Founded in 1982, GHESKIO (Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, or the Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections) is a nongovernmental research and training center internationally recognized for its pioneering work in the treatment of HIV and AIDS-related illnesses. GHESKIO maintains a close relationship with Weill Cornell Medical College. Its founding director, Dr. Jean Pape, is a professor of medicine at Weill Cornell Medical College. Since its inception, GHESKIO has never closed its doors to patients, not even during the 7.0 magnitude earthquake that struck Haiti in 2010.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
- Serena P. Koenig, Heejung Bang, Patrice Severe, Marc Antoine Jean Juste, Alex Ambroise, Alison Edwards, Jessica Hippolyte, Daniel W. Fitzgerald, Jolion McGreevy, Cynthia Riviere, Serge Marcelin, Rode Secours, Warren D. Johnson, Jean W. Pape, Bruce R. Schackman. Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti. PLoS Medicine, 2011; 8 (9): e1001095 DOI: 10.1371/journal.pmed.1001095
Note: If no author is given, the source is cited instead.